Aptorum Group Ltd Class A
$ 1.37
5.38%
03 Dec - close price
- Market Cap 11,156,900 USD
- Current Price $ 1.37
- High / Low $ 1.39 / 1.27
- Stock P/E N/A
- Book Value 3.24
- EPS -0.36
- Next Earning Report 2025-12-18
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.06 %
- ROE -0.14 %
- 52 Week High 4.47
- 52 Week Low 0.67
About
Aptorum Group Ltd Class A is an innovative biotechnology company headquartered in London, specializing in the discovery, development, and commercialization of advanced therapeutic solutions aimed at addressing critical health challenges such as infectious diseases and cancer. The company has developed a strong pipeline of proprietary drug candidates, supported by state-of-the-art research and technology, highlighting its dedication to filling significant unmet medical needs. With a strategic focus on expediting the transition of novel therapies to market, Aptorum Group is poised to significantly impact the pharmaceutical landscape and improve health outcomes for patients globally.
Analyst Target Price
$80.00
Quarterly Earnings
| Mar 2025 | Sep 2024 | Mar 2023 | Jun 2022 | Mar 2022 | Jun 2021 | Mar 2021 | Dec 2020 | Sep 2020 | Jun 2020 | Mar 2020 | Dec 2019 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-04-30 | 2024-12-20 | 2023-04-28 | 2022-09-30 | 2022-04-29 | 2021-09-15 | 2021-04-19 | 2021-03-31 | 2020-12-31 | 2020-09-01 | 2020-04-29 | 2020-03-31 |
| Reported EPS | -0.29 | -0.5 | -2.22 | -0.05 | -0.25 | -0.47 | 0.38 | -0.2346 | 0.1889 | -0.21 | -0.33 | -0.1036 |
| Estimated EPS | 0 | 0 | None | -3 | -3.3 | -3 | -3.1 | 0 | 0 | 0 | 0 | 0 |
| Surprise | -0.29 | -0.5 | 0 | 2.95 | 3.05 | 2.53 | 3.48 | -0.2346 | 0.1889 | -0.21 | -0.33 | -0.1036 |
| Surprise Percentage | None% | None% | None% | 98.3333% | 92.4242% | 84.3333% | 112.2581% | None% | None% | None% | None% | None% |
Next Quarterly Earnings
| Sep 2025 | |
|---|---|
| Reported Date | 2025-12-18 |
| Fiscal Date Ending | 2025-09-30 |
| Estimated EPS | |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: APM
2025-11-02 11:40:18
DiamiR Biosciences and Aptorum Group announced that DiamiR received a Clinical Laboratory Evaluation Program (CLEP) Test Approval for its APOE Genotyping test from the New York State Department of Health (NYSDOH). This approval allows DiamiR to offer its validated APOE Genotyping molecular testing in various biological samples through its CLIA-certified and CAP-accredited clinical laboratory to licensed healthcare providers in New York State and nationwide. The milestone enhances diagnostics capabilities for the merging companies.
2025-10-26 05:02:20
This article provides a detailed stock quote and forecast for Aptorum Group Limited Class A (APM). It covers current and after-hours trading prices, key stock statistics, company information, financial data, and analyst ratings, including a 1-year stock price forecast. The report also lists several competitors in the Health Technology sector.
2025-10-26 05:02:20
Aptorum Group (APM) has regained compliance with Nasdaq's minimum bid price requirement by maintaining a closing bid price of at least $1.00 for ten consecutive business days between July 16 and July 30, 2025. This resolution addresses an earlier notice from Nasdaq dated April 15, 2025. Additionally, Aptorum announced a definitive all-stock merger agreement with DiamiR Biosciences, a company specializing in blood-based brain health tests, which will become a wholly-owned subsidiary of Aptorum.
2025-10-26 05:02:20
Aptorum Group Limited announced its intention to acquire URF Holding Group Limited, a company focused on urban revitalization in China, through a non-binding Letter of Intent and Term Sheet. The acquisition, which involves a reverse takeover, will result in Aptorum distributing its existing businesses to pre-acquisition shareholders. U Group's strategy targets China's "Generation Z" consumption growth through curated shopping experiences and community rejuvenation, with significant revenues reported for 2020 and 2021.
2025-10-26 05:02:20
Aptorum Group Limited announced the completion of a private offering of a $3 million convertible note due in December 2023. The note was solely subscribed by Aenco Technologies Limited, an entity indirectly owned by Aptorum's Non-Executive Director and major shareholder, Mr. Ian Huen. Proceeds will fund research and development of therapeutic candidates, its liquid biopsy diagnostics program, commercialization of NativusWell®, and general corporate purposes.
2025-10-26 05:02:20
YOOV Group Holding Limited has cancelled its acquisition of Aptorum Group Limited in a reverse merger transaction that was initially announced on March 1, 2024. The deal, valued at $250 million, would have resulted in YOOV shareholders owning approximately 90% of the combined company. As part of the termination agreement, YOOV is required to reimburse Aptorum for 90% of incurred expenses, up to $1,000,000.
